Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Crystal S Denlinger

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
British Journal of Cancer|March 11, 2020
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trialsNamrata Vijayvergia, Arvind Dasari, Mengying Deng, et al.
The Lancet. Oncology|June 5, 2025
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 studyElena Elimova, Jaffer Ajani, Howard Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid TumorsAni S Balmanoukian, Jeffrey R Infante, Raid Aljumaily, et al.
JCO Clinical Cancer Informatics|January 25, 2021
Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal CancerWilliam H Ward, Caitlin R Meeker, Elizabeth Handorf, et al.
Clinical Colorectal Cancer|September 25, 2020
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal CancerArthur Winer, Crystal S Denlinger, Namrata Vijayvergia, et al.
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Nature Communications|July 27, 2023
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumorsMatthew Zibelman, Alexander W MacFarlane, Kimberly Costello, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2011
NCCN Clinical Practice Guidelines Occult primaryDavid S Ettinger, Mark Agulnik, Justin M M Cates, et al.
Liver Cancer|March 27, 2025
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar CarcinomaGhassan K Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, et al.
JNCI Cancer Spectrum|April 8, 2020
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)Justin C Brown, Sui Zhang, Fang-Shu Ou, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
British Journal of Cancer|March 11, 2020
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trialsNamrata Vijayvergia, Arvind Dasari, Mengying Deng, et al.
The Lancet. Oncology|June 5, 2025
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 studyElena Elimova, Jaffer Ajani, Howard Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid TumorsAni S Balmanoukian, Jeffrey R Infante, Raid Aljumaily, et al.
JCO Clinical Cancer Informatics|January 25, 2021
Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal CancerWilliam H Ward, Caitlin R Meeker, Elizabeth Handorf, et al.
Clinical Colorectal Cancer|September 25, 2020
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal CancerArthur Winer, Crystal S Denlinger, Namrata Vijayvergia, et al.
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Nature Communications|July 27, 2023
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumorsMatthew Zibelman, Alexander W MacFarlane, Kimberly Costello, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2011
NCCN Clinical Practice Guidelines Occult primaryDavid S Ettinger, Mark Agulnik, Justin M M Cates, et al.
Liver Cancer|March 27, 2025
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar CarcinomaGhassan K Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, et al.
JNCI Cancer Spectrum|April 8, 2020
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)Justin C Brown, Sui Zhang, Fang-Shu Ou, et al.
Pageof 10